drugset / Trial / NCT00493896

Safety of Fondaparinux as Routine VTE Prophylaxis in Medical ICU Patients

NCT00493896

RandomizedParallel-groupDouble-blindPrevention

Summary

This is a pilot study to evaluate safety of fondaparinux and enoxaparin in terms of bleeding and development of thrombocytopenia in the medical ICU population.

Timeline

Start
2007-07
Primary completion
2010-04
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Enoxaparin sodium Other / unclassified 40 mg Subcutaneous
Subject Fondaparinux Other / unclassified 2.5 mg Subcutaneous